Iradimed (NASDAQ:IRMD) Issues Q1 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.390-0.430 for the period, compared to the consensus EPS estimate of 0.410. The company issued revenue guidance of $19.2 million-$19.4 million, compared to the consensus revenue estimate of $19.1 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Stock Down 0.3 %

Shares of IRMD opened at $55.23 on Friday. The company has a market cap of $699.76 million, a PE ratio of 37.83 and a beta of 0.82. The business has a fifty day moving average of $57.20 and a 200 day moving average of $52.10. Iradimed has a 52-week low of $40.18 and a 52-week high of $63.29.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05). Iradimed had a return on equity of 23.99% and a net margin of 26.12%. As a group, research analysts anticipate that Iradimed will post 1.52 earnings per share for the current fiscal year.

Iradimed Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 5th. Shareholders of record on Monday, February 24th will be paid a $0.17 dividend. This is a positive change from Iradimed’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Monday, February 24th. This represents a $0.68 dividend on an annualized basis and a yield of 1.23%. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. StockNews.com lowered Iradimed from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Roth Mkm restated a “buy” rating and set a $72.00 price target (up previously from $60.00) on shares of Iradimed in a research note on Friday.

Insider Activity

In other Iradimed news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.